Compare Lithium Americas Corp (LAC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs TransMedics Group Inc — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 3.2× Lithium Americas Corp's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and TransMedics Group Inc for 24 Days on average.
| LAC | TMDX | |
|---|---|---|
Market Cap | $850.38M | $2.74B |
Volume | 8,804,637 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $150.42 |
52-Week Low | $2.35 | $61.99 |
Typical Hold Time | 27 Days | 24 Days |
Enterprise Value | $1.19B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, while maintaining strong analyst support with 7 buy ratings and a $4.00 consensus price target. Recent financing activities and Thacker Pass project development provide growth catalysts amid challenging lithium market conditions.
LAC presents a high-risk opportunity with significant upside potential from its Thacker Pass project execution, though negative cash flow and lithium price volatility create near-term headwinds. The stock trades at a discount to analyst targets but requires successful project ramp-up to justify valuation.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
